Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Roche launches "future proof" Chlamydia test in Europe

This article was originally published in Clinica

  • News

Executive Summary

Roche Diagnostics has launched its Cobas TaqMan CT Test v2.0 in Europe. It CE marked the diagnostic, for detecting Chlamydia trachomatis, in June. Basel, Switzerland-based Roche claims the test is "future-proof", meaning it still produces reliable results even when mutations occur in the bacteria's cryptic plasmid DNA. It does this by simultaneously detecting two targets within the C trachomatis cryptic plasmid and genome target DNA. Plasmids are outside a bacteria's chromosomal DNA and are capable of replicating independently. The test is run on the Cobas TaqMan 48 analyser, which can carry out 48 tests per run with results available in 2.5 hours.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

ORA’s Chief Says Without Additional Funding, Inspections Are In Jeopardy

News We’re Watching: Philips Settles Recall Fallout; FDA REdI, Townhalls, Approvals

ICER Debuts Clinical Trial Diversity Assessment Framework

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

See All
UsernamePublicRestriction

Register

MT043477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By